Inmune Bio, Inc. (INMB) shareholders
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Xencor, Inc. | 1,885,533 | 9.60% | 13G (passive) amendment | Dec 31, 2023 |
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (5.50%) | 1,500,000 | 5.50% | 13G (passive) | Jun 27, 2025 |
| Highbridge Capital Management, LLC | 1,454,400 | 5.20% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 706,424 | 2.55% | $1.15M | +19,409 | 0.00% |
| Aqr Capital Management LLC | 662,218 | 2.39% | $1.08M | +391,901 | 0.00% |
| BlackRock, Inc. | 311,613 | 1.12% | $507.93K | −882,499 | 0.00% |
| Raymond James Financial Inc | 212,995 | 0.77% | $347.18K | +9,750 | 0.00% |
| Geode Capital Management, LLC | 190,215 | 0.69% | $310.28K | −304,754 | 0.00% |
| Goldman Sachs Group Inc | 185,245 | 0.67% | $301.95K | −46,341 | 0.00% |
| Millennium Management LLC | 159,559 | 0.57% | $260.08K | New | 0.00% |
| Susquehanna International Group, Llp | 158,452 | 0.57% | $258.28K | −35,939 | 0.00% |
| Jane Street Group, LLC | 134,232 | 0.48% | $218.80K | +83,288 | 0.00% |
| UBS Group AG | 110,413 | 0.40% | $179.97K | −142,927 | 0.00% |
| Westside Investment Management, Inc. | 108,300 | 0.39% | $176.54K | – | 0.02% |
| Citadel Advisors LLC | 106,231 | 0.38% | $173.16K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 104,775 | 0.38% | $170.78K | −18,409 | 0.00% |
| State Street Corp | 93,363 | 0.34% | $152.18K | −197,516 | 0.00% |
| Hrt Financial LP | 84,358 | 0.30% | $137.00K | New | 0.00% |
| Ieq Capital, LLC | 82,385 | 0.30% | $134.29K | +57,822 | 0.00% |
| Gsa Capital Partners Llp | 81,991 | 0.30% | $134.00K | New | 0.01% |
| Virtu Financial LLC | 75,212 | 0.27% | $123.00K | New | 0.00% |
| Laird Norton Trust Company, LLC | 52,000 | 0.19% | $84.76K | +2,000 | 0.00% |
| Buckingham Strategic Partners | 43,556 | 0.16% | $71.00K | +531 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 83 | 4M | 15.7% | 24 / 26 | 22 / 21 | 1M | 2M |
| Q1 2026 | 82 | 5M | 19.4% | 18 / 25 | 21 / 9 | 2M | 1M |
| Q4 2025 | 74 | 5M | 18.3% | 12 / 24 | 20 / 10 | 1M | 0M |
| Q3 2025 | 73 | 5M | 17.0% | 16 / 21 | 22 / 22 | 1M | 2M |
| Q2 2025 | 79 | 6M | 20.4% | 19 / 29 | 15 / 22 | 2M | 2M |
| Q1 2025 | 82 | 6M | 22.2% | 18 / 25 | 22 / 8 | 1M | 1M |
| Q4 2024 | 73 | 6M | 22.8% | 15 / 34 | 7 / 8 | 2M | 0M |
| Q3 2024 | 67 | 5M | 19.3% | 19 / 29 | 7 / 7 | 2M | 0M |
| Q2 2024 | 57 | 5M | 16.5% | 19 / 15 | 12 / 14 | 3M | 1M |
| Q1 2024 | 52 | 3M | 10.1% | 11 / 17 | 11 / 7 | 1M | 0M |
| Q4 2023 | 48 | 2M | 8.3% | 14 / 14 | 9 / 3 | 0M | 0M |
| Q3 2023 | 37 | 2M | 7.7% | 7 / 8 | 10 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
62 funds held INMB in Q1 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 490,268 | 1.77% | $799.14K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 195,995 | 0.71% | $319.47K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 113,711 | 0.41% | $160.33K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 113,297 | 0.41% | $159.75K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 81,590 | 0.29% | $132.99K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 29,204 | 0.11% | $41.18K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 26,591 | 0.10% | $37.49K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 20,161 | 0.07% | $32.86K | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 19,552 | 0.07% | $27.57K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 10,829 | 0.04% | $15.27K | 0.00% | May 31, 2026 |
| Small Cap Index Fund | 7,131 | 0.03% | $10.05K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 5,575 | 0.02% | $9.09K | 0.00% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 2,925 | 0.01% | $4.77K | 0.00% | Jun 30, 2026 |
| ProShares Russell 2000 High Income ETF | 1,048 | 0.00% | $1.48K | 0.00% | May 31, 2026 |
| ProShares UltraPro Russell2000 | 829 | 0.00% | $1.17K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David J. Moss | Chief Executive Officer, Director | 1,294,883 | 4.67% | Jul 7, 2026 |
| Raymond Joseph Tesi | President and CEO, Director, 10% owner | 1,554,106 | 5.60% | Dec 9, 2024 |
| Mark William Lowdell | Chief Scientific Officer | 1,518,017 | 5.47% | Jul 7, 2026 |
| Cory Randall Ellspermann | CFO | – | – | Dec 2, 2025 |
| Ronnie Duane Clark | Director | – | – | Sep 23, 2026 |
| James Sapirstein | Director | – | – | Sep 17, 2026 |
| Scott Juda | Director | 158,007 | 0.57% | Jul 7, 2026 |
| Marcia Allen | Director | – | – | Dec 2, 2025 |
| Timothy j. Schroeder | Director | 82,187 | 0.30% | Dec 2, 2025 |
| James Kelly Ganjei | Director | 17,793 | 0.06% | Dec 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark William Lowdell Chief Scientific Officer | Jul 2, 2026 | Option exercise | +7,211 | $1.40 | $10.10K | 1,518,017 |
| Scott Juda Director | Jul 2, 2026 | Option exercise | +14,801 | $1.40 | $20.72K | 86,404 |
| David J. Moss Chief Executive Officer, Director | Jul 2, 2026 | Option exercise | +9,014 | $1.40 | $12.62K | 1,294,883 |
| David J. Moss Chief Financial Officer, 10% owner | Sep 30, 2024 | Buy | +10,000 | $5.29 | $52.90K | 1,285,869 |
| David J. Moss Chief Financial Officer, 10% owner | Sep 12, 2024 | Buy | +7,690 | $6.38 | $49.06K | 1,275,869 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Sep 12, 2024 | Buy | +15,380 | $6.38 | $98.12K | 1,554,106 |
| Scott Juda Director | Jun 25, 2024 | Buy | +5,000 | $7.27 | $36.35K | 71,603 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Apr 19, 2024 | Buy | +18,028 | $8.32 | $149.99K | 1,538,726 |
| Scott Juda Director | Apr 19, 2024 | Buy | +29,603 | $8.32 | $246.30K | 66,603 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Apr 19, 2024 | Buy | +18,028 | $8.32 | $149.99K | 1,268,179 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Apr 19, 2024 | Buy | +14,423 | $8.32 | $120.00K | 1,510,806 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Apr 19, 2024 | Award | +14,423 | $8.32 | $120.00K | 1,510,806 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Apr 19, 2024 | Award | +18,028 | $8.32 | $149.99K | 1,268,179 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Apr 19, 2024 | Award | +18,028 | $8.32 | $149.99K | 1,538,726 |
| Scott Juda Director | Apr 19, 2024 | Award | +29,603 | $8.32 | $246.30K | 66,603 |
| Scott Juda Director | Nov 10, 2023 | Buy | +7,000 | $6.95 | $48.65K | 37,000 |
| Timothy j. Schroeder Director | Jul 12, 2023 | Sale(10b5-1 plan) | −10,000 | $11.01 | $110.10K | 82,187 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Mar 17, 2023 | Buy | +2,500 | $6.43 | $16.08K | 1,250,151 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | May 27, 2022 | Buy | +3,000 | $6.79 | $20.37K | 1,247,651 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | May 26, 2022 | Buy | +7,700 | $6.27 | $48.28K | 1,244,651 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | May 26, 2022 | Buy | +6,300 | $6.41 | $40.38K | 1,520,698 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Mar 22, 2022 | Award | +23,724 | $8.43 | $199.99K | 1,514,398 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Mar 22, 2022 | Award | +17,793 | $8.43 | $149.99K | 1,236,951 |
| James Kelly Ganjei Director | Mar 22, 2022 | Award | +17,793 | $8.43 | $149.99K | 17,793 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Mar 22, 2022 | Award | +23,590 | $8.43 | $198.86K | 1,496,383 |
| Scott Juda Director | Nov 17, 2021 | Buy | +2,500 | $13.55 | $33.88K | 30,000 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Nov 3, 2021 | Sale(10b5-1 plan) | −1,025 | $20.00 | $20.50K | 1,219,158 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Nov 3, 2021 | Sale(10b5-1 plan) | −701 | $20.00 | $14.02K | 1,472,793 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Nov 3, 2021 | Sale(10b5-1 plan) | −3,626 | $20.00 | $72.52K | 1,490,674 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Oct 27, 2021 | Sale(10b5-1 plan) | −2,079 | $20.00 | $41.58K | 1,220,183 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Oct 27, 2021 | Sale(10b5-1 plan) | −6,517 | $20.00 | $130.34K | 1,494,300 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Oct 27, 2021 | Sale(10b5-1 plan) | −2,357 | $20.00 | $47.14K | 1,473,494 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Oct 25, 2021 | Sale(10b5-1 plan) | −13 | $20.00 | $260 | 1,222,262 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Oct 22, 2021 | Sale(10b5-1 plan) | −400 | $20.00 | $8.00K | 1,475,851 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Oct 22, 2021 | Sale(10b5-1 plan) | −23,616 | $20.00 | $472.32K | 1,500,817 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Oct 22, 2021 | Sale(10b5-1 plan) | −1,142 | $20.00 | $22.84K | 1,222,275 |
| Inc Xencor 10% owner | Sep 3, 2021 | Option exercise | +108,000 | $7.80 | $842.40K | 1,885,533 |
| Raymond Joseph Tesi President and CEO, Director, 10% owner | Aug 25, 2021 | Option exercise | +30,000 | $3.91 | $117.30K | 1,524,433 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Jul 16, 2021 | Option exercise | +25,000 | $3.91 | $97.75K | 1,223,417 |
| Timothy j. Schroeder Director | Jul 13, 2021 | Sale(10b5-1 plan) | −14,480 | $27.63 | $400.08K | 92,187 |
| Timothy j. Schroeder Director | Jul 9, 2021 | Sale(10b5-1 plan) | −30,000 | $23.21 | $696.30K | 106,667 |
| Mark William Lowdell Chief Scientific Officer | Jul 8, 2021 | Sale(10b5-1 plan) | −24,150 | $20.19 | $487.59K | 1,476,251 |
| David J. Moss CFO, Treasurer & Secretary | Jul 8, 2021 | Sale(10b5-1 plan) | −16,302 | $20.09 | $327.51K | 1,198,417 |
| Raymond Joseph Tesi President and CEO, Director | Jul 8, 2021 | Sale(10b5-1 plan) | −24,351 | $20.08 | $488.97K | 1,510,933 |
| Mark William Lowdell Chief Scientific Officer | Jul 7, 2021 | Sale(10b5-1 plan) | −5,850 | $20.02 | $117.12K | 1,500,401 |
| David J. Moss CFO, Treasurer & Secretary | Jul 7, 2021 | Sale(10b5-1 plan) | −8,698 | $20.01 | $174.05K | 1,214,719 |
| Raymond Joseph Tesi President and CEO, Director | Jul 7, 2021 | Sale(10b5-1 plan) | −5,649 | $20.02 | $113.09K | 1,535,284 |
| Timothy j. Schroeder Director | Jun 14, 2021 | Sale(10b5-1 plan) | −10,000 | $19.02 | $190.20K | 136,667 |
| Inc Xencor 10% owner | Jun 10, 2021 | Other | +192,533 | $17.14 | $3.30M | 1,777,533 |
| Inc Xencor 10% owner | Jun 10, 2021 | Other | +192,533 | $17.14 | $3.30M | 1,777,533 |
| Inc Xencor 10% owner | Jun 10, 2021 | Other | +192,532 | $17.14 | $3.30M | – |
| Timothy j. Schroeder Director | Jun 10, 2021 | Sale(10b5-1 plan) | −10,000 | $17.01 | $170.10K | 146,667 |
| Timothy j. Schroeder Director | Mar 31, 2021 | Sale | −10,000 | $11.95 | $119.50K | 156,667 |
| Linda F. Powers 10% owner | Jan 27, 2020 | Sale | −220,000 | $4.60 | $1.01M | 210,000 |
| Mark William Lowdell Chief Scientific Officer, 10% owner | Sep 11, 2019 | Buy | +2,918 | $6.23 | $18.18K | 1,506,251 |
| Scott Juda Director | Aug 21, 2019 | Buy | +2,500 | $6.00 | $15.00K | 27,500 |
| Scott Juda Director | Aug 20, 2019 | Buy | +2,500 | $6.00 | $15.00K | 25,000 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Aug 20, 2019 | Buy | +376 | $5.65 | $2.12K | 1,223,417 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Aug 20, 2019 | Buy | +236 | $5.65 | $1.33K | 1,223,041 |
| David J. Moss CFO, Treasurer & Secretary, 10% owner | Aug 20, 2019 | Buy | +77 | $5.65 | $435 | 1,220,494 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inmune Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,253 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| CTI Holdings, Inc Director | Jul 12, 2023 | 60,000 | $960.09K | Jul 12, 2023 | STOCK PURCHASE |
See a number that looks wrong?